Çildağ MB, Köseoğlu ÖF, Akdam H, Yeniçerioğlu Y. The primary patency of drug-eluting balloon versus conventional balloon angioplasty in hemodialysis patients with arteriovenous fistula stenoses. Jpn J Radiol 2016;34:700-704.
Khawaja AZ, Cassidy DB, Al Shakarchi J, McGrogan DG, Inston NG, Jones RG. Systematic review of drug eluting balloon angioplasty for arteriovenous haemodialysis access stenosis. J Vasc Access 2016;17:103-110.
Swinnen J, Lean Tan K, Allen R, Burgess D, Mohan IV. Juxta-anastomotic stenting with aggressive angioplasty will salvage the native radiocephalic fistula for dialysis. J Vasc Surg 2015;61:436-442.
Kitrou P, Spiliopoulos S, Karnabatidis D, Katsanos K. Cutting balloons, covered stents and paclitaxel-coated balloons for the treatment of dysfunctional dialysis access. Expert Rev Med Devices 2016;13:1119-1126.
Roy-Chaudhury P, Spergel LM, Besarab A, Asif A, Ravani P. Biology of arteriovenous fistula failure. J Nephrol 2007;20:150-163.
Duque JC, Tabbara M, Martinez L, Cardona J, Vazquez-Padron RI, Salman LH. Dialysis arteriovenous fistula failure and angioplasty: intimal hyperplasia and other causes of access failure. Am J Kidney Dis 2017;69:147-151.
National Kidney Foundation. 2006 Updates to clinical practice guidelines and recommendations: vascular access. The National Kidney Foundation Kidney Disease Outcomes Quality Initiative (NKF KDOQI); 2006:244e50.
Chang CJ, Ko PJ, Hsu LA, Ko YS, Ko YL, Chen CF, et al. Highly increased cell proliferation activity in the restenotic hemodialysis vascular access after percutaneous transluminal angioplasty: implication in prevention of restenosis. Am J Kidney Dis 2004;43:74-84.
Trerotola SO, Lawson J, Roy-Chaudhury P, Saad TF. Drug coated balloon angioplasty in failing AV fistulas: a randomized controlled trial. Clin J Am Soc Nephrol 2018;13:1215-1224.
Swinnen JJ, Hitos K, Kairaitis L, Gruenewald S, Larcos G, Farlow D, et al. Multicentre, randomised, blinded, control trial of drug-eluting balloon vs Sham in recurrent native dialysis fistula stenoses. J Vasc Access 2019;20:260-269.
Agarwal AK, Thakkar A, Haddad NJ. How is arteriovenous fistula longevity best prolonged?: the role of percutaneous balloon angioplasty. Semin Dial 2015;28:27-29.
Yevzlin AS, Melnick DM. How is arteriovenous fistula longevity best prolonged?: the role of endovascular stents. Semin Dial 2015;28:29-32.
Ozkan B, Güngör D, Yıldırım UM, Harman A, Ozen O, Aytekin C. Endovascular stent placement of juxtaanastomotic stenosis in native arteriovenous fistula after unsuccessful balloon angioplasty. Iran J Radiol 2013;10:133-139.
McLennan G. Stent and stent-graft use in arteriovenous dialysis access. Semin Intervent Radiol 2016;33:10-14.
Laird JR, Hong M. Drug-eluting stents in the superficial femoral artery: the long and winding road. Circulation 2016;133:1435-1437.
Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002;346:1773-1780.
Gray WA, Keirse K, Soga Y, Benko A, Babaev A, Yokoi Y, et al. A polymer-coated, paclitaxel-eluting stent (Eluvia) versus a polymer-free, paclitaxel-coated stent (Zilver PTX) for endovascular femoropopliteal intervention (IMPERIAL): a randomised, non-inferiority trial. Lancet 2018;392:1541-1551.
Thomas SD, Ip EC, Katib N, Pugh D, Lennox A, Endre Z, et al. A comprehensive renal vascular access clinic results in improved patient outcomes and reduced costs. ANZ J Surg 2018;88:185-190.
Sidawy AN, Gray R, Besarab A, Henry M, Ascher E, Silva M Jr, et al. Recommended standards for reports dealing with arteriovenous hemodialysis accesses. J Vasc Surg 2002;35:603-610.
Katsanos K, Karnabatidis D, Kitrou P, Spiliopoulos S, Christeas N, Siablis D. Paclitaxel-coated balloon angioplasty vs. plain balloon dilation for the treatment of failing dialysis access: 6-month interim results from a prospective randomized controlled trial. J Endovasc Ther 2012;19:263-272.
Kitrou PM, Spiliopoulos S, Katsanos K, Papachristou E, Siablis D, Karnabatidis D. Paclitaxel-coated versus plain balloon angioplasty for dysfunctional arteriovenous fistulae: one-year results of a prospective randomized controlled trial. J Vasc Interv Radiol 2015;26:348-354.
Swinnen JJ, Zahid A, Burgess DC. Paclitaxel drug-eluting balloons to recurrent in-stent stenoses in autogenous dialysis fistulas: a retrospective study. J Vasc Access 2015;16:388-393.
Massmann A, Fries P, Obst-Gleditsch K, Minko P, Shayesteh-Kheslat R, Buecker A. Paclitaxel-coated balloon angioplasty for symptomatic central vein restenosis in patients with hemodialysis fistulas. J Endovasc Ther 2015;22:74-79.
Boitet A, Massy ZA, Goeau-Brissonniere O, Javerliat I, Coggia M, Coscas R. Drug-coated balloon angioplasty for dialysis access fistula stenosis. Semin Vasc Surg 2016;29:178-185.
Ulloa JG, Kirkpatrick VE, Wilson SE, Williams RA. Stent salvage of arteriovenous fistulas and grafts. Vasc Endovascular Surg 2014;48:234-238.
Dinh K, Limmer AM, Paravastu SCV, Thomas SD, Bennett MH, Holden A, et al. Mortality after paclitaxel-coated device use in dialysis access: a systematic review and meta-analysis. J Endovasc Ther 2019;26:600-612.
Guyatt GH, Akl EA, Crowther M, Gutterman DD, Schuünemann HJ. Executive summary: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012;141(2 Suppl):7S-47S.
Yang JK, Jimenez JC, Jabori S. Antiplatelet therapy before, during, and after extremity revascularization. J Vasc Surg 2014;60:1085-1091.
Kronlage M, Wassmann M, Vogel B, Müller OJ, Blessing E, Katus H, et al. Short vs prolonged dual antiplatelet treatment upon endovascular stenting of peripheral arteries. Drug Des Devel Ther 2017;11:2937-2945.
Sharma A, Agrawal S, Garg A, Vallakati A, Lavie CJ, Helft G. Duration of dual antiplatelet therapy following drug-eluting stent implantation: a systemic review and meta-analysis of randomized controlled trials with longer follow up. Catheter Cardiovasc Interv 2017;90:31-37.